3 Results for "

pRB phosphorylation

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "pRB phosphorylation" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-158106
CAS No.: 3047321-53-6
Purity:  99.60%
Synonyms: AZD8421
Target:  

CDK

Research Areas:  

Cancer

Gatsuciclib (AZD8421) is a selective CDK2 inhibitor (IC50 = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9). Gatsuciclib has no significant kinase inhibition outside the CDK family. Gatsuciclib inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. Gatsuciclib can be studied in research for breast cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-201330
CAS No.: 2531743-46-9
Synonyms: RGT-419B
Target:  

CDK

Research Areas:  

Cancer

GDC-4198 (RGT-419B) is an orally active CDK4/2 inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .
loading...
    loading...
Cat. No.: HY-186132
CAS No.: 3030276-48-0
Target:  

PROTACs CDK

Research Areas:  

Cancer

PROTAC CDK2-pRb degrader-1 is an orally active PROTAC-class degrader of CDK2. PROTAC CDK2-pRb degrader-1 effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine residues 807/811 by inducing ubiquitination and proteasomal degradation of CDK2. PROTAC CDK2-pRb degrader-1 exhibits significant activity against human cells (with EC50 values of 12 nM and 125 nM, respectively). In xenograft models, PROTAC CDK2-pRb degrader-1 effectively inhibits tumor growth and induces tumor stasis, making it suitable for research related to CCNE1-amplified cancers (such as ovarian cancer, gastric cancer, and breast cancer) .
loading...
    loading...